Current
Research in
Ophthalmology >>

A two year open label, randomized, parallel group, blinded assessment ophthalmologic safety study of pramipexole IR versus ropinirole in early Parkinson's Disease patients

Principal Investigator

Alessandra Bertolucci, MD

Enrollment Status

Completed

Objective

Synthetic dopamine agonists including study drugs have shown benefit in Parkinson's Disease (PD) as an adjuvant therapy. Drugs affect neurotransmitters in the retina where dopamine has been shown to be reduced and dependant neurons appear swollen and distorted. This study is designed as a longitudinal study to rule out effects on the retina.

Study results are currently being analyzed. Please visit this webpage next month for the study update. For more information: ClinicalTrials.gov  

Home > Current Research > Clinical Trials in Ophthalmology > Results > A two year open label, randomized, parallel group, blinded assessment ophthalmologic safety study of pramipexole IR versus ropinirole in early Parkinson's Disease patients